EdgarTurnerOvertonMD

Infectious Disease • Birmingham, AL

Assistant Professor, Medicine, University of Alabama School of Medicine

Join to view full profile

Dr. Overton is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Overton's full profile

Already have an account?

Office
1717 6th Ave S
Birmingham, AL 35233
Phone+1 800-822-8816

Fax+1 314-975-6027

Education & Training

Washington University/B-JH/SLCH ConsortiumFellowship, Infectious Disease, 2002 - 2004
University of Alabama Medical CenterResidency, Internal Medicine, 1999 - 2002
University of Tennessee Health Science Center College of MedicineClass of 1999

Certifications & Licensure

AL State Medical License 2001 - 2024
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Infectious Disease

Clinical Trials

Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals
Completed
Phase 2
Safety and Immunogenicity of IMVAMUNE® (MVA-BN®) Smallpox Vaccine in HIV Infected Patients Start of enrollment: 2006 Jun 01
Completed
Phase 2
High Dose Vitamin D and Calcium for Bone Health in Individuals Initiating HAART Start of enrollment: 2011 Sep 01
Completed
Phase 2
Safety Study of FluMist With and Without Ampligen Start of enrollment: 2012 Apr 01
Terminated
Phase 1, Phase 2
FTC/RPV/TDF on T-Cell Activation, CD4+ T-Cell Count, Inflammatory Biomarkers and Viral Reservoir Start of enrollment: 2013 Apr 25
Completed
Phase 4
Effect of Isotretinoin on Immune Activation Among HIV-1 Infected Subjects With Incomplete CD4+ T Cell Recovery Start of enrollment: 2014 Jul 02
Completed
Phase 2
Randomized, Open-label Phase II Trial to Assess the Safety and Immunogenicity of MVA-BN Smallpox Vaccine in Immunocompromised Subjects With HIV Infection Start of enrollment: 2014 Apr 28
Completed
Phase 2
Effects of the Probiotic Visbiome Extra Strength on Gut Microbiome & Immune Activation Markers Start of enrollment: 2016 Apr 01
Completed
Phase 2
PREPARE (A5361s) Substudy of REPRIEVE (A5332) Start of enrollment: 2017 Feb 28
Completed
Join now to see all

Publications & Presentations

PubMed

58 citations
Factors associated with renal dysfunction within an urban HIV-infected cohort in the era of highly active antiretroviral therapy.
Edgar T. Overton, Diana Nurutdinova, J. Freeman, Warren Seyfried, Kristin Mondy
HIV Medicine. 2009-03-11
73 citations
Brief Report: The Right People, Right Places, and Right Practices: Disparities in PrEP Access Among African American Men, Women, and MSM in the Deep South.
Latesha Elopre, Kachina Kudroff, Andrew O. Westfall, Edgar T. Overton, Michael J. Mugavero
Journal of Acquired Immune Deficiency Syndromes. 2017-01-01
93 citations
Metabolic Complications and Glucose Metabolism in HIV Infection: A Review of the Evidence.
Amanda L. Willig, Edgar T. Overton
Current HIV/AIDS Reports. 2016-08-19

Journal Articles

Immunogenicity and Safety of Three Consecutive Production Lots of the Non Replicating Smallpox Vaccine MVA: A Randomised, Double Blind, Placebo Controlled Phase III Trial
Edgar Turner Overton, Steven J Lawrence, PLoS One
The Impact of Statin and Angiotensin-Converting Enzyme Inhibitor/Angiotensin Receptor Blocker Therapy on Cognitive Function in Adults with Human Immunodeficiency Virus...
C William Wester, Edgar Turner Overton, Susan L Koletar, Kristine M Erlandson, Constance A Benson, Robert C Kalayjian, Clinical Infectious Diseases

Lectures

Screening in Emergency Department Identifies a Large Cohort of Unrecognized Chronic Hepatitis C Virus Infection among Baby Boomers
University of Alabama at Birmingham, Birmingham, AL - 5/15/2014

Press Mentions

Probiotic to Be Studied in People Living with HIVAugust 24th, 2015
Probiotic to Be Studied in People Living with HIVFebruary 12th, 2016
Modern Integrase Inhibitor Regimens Work Well over the Long TermJune 21st, 2023